Clinical validation of the Tempus xO assay-Reference-Cited by-同舟云学术

Clinical validation of the Tempus xO assay

Published:2018-05-25 Issue:40 Volume:9 Page:25826-25832
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Beaubier Nike¹,Tell Robert¹,Huether Robert¹,Bontrager Martin¹,Bush Stephen¹,Parsons Jerod¹,Shah Kaanan¹,Baker Tim¹,Selkov Gene¹,Taxter Tim¹,Thomas Amber¹,Bettis Sam¹,Khan Aly¹,Lau Denise¹,Lee Christina¹,Barber Matthew¹,Cieslik Marcin²,Frankenberger Casey¹,Franzen Amy¹,Weiner Ali¹,Palmer Gary¹,Lonigro Robert²,Robinson Dan²,Wu Yi-Mi²,Cao Xuhong²,Lefkofsky Eric¹,Chinnaiyan Arul²³,White Kevin P.¹

Affiliation:

1. Tempus Labs, Inc., Chicago, Illinois 60654, USA

2. Department of Pathology and Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA

3. Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinical, Morphologic, and Molecular Spectrum of BRAF Fusion Spitz Tumors;American Journal of Surgical Pathology;2024-08-22

2. Genetic Ancestry and Somatic Mutations in Lung Adenocarcinoma: Insights from Real-World Clinico-Genomic Data;2024-04-25

3. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms;American Journal of Surgical Pathology;2024-03-25

4. Beta-defensin index: A functional biomarker for oral cancer detection;Cell Reports Medicine;2024-03

5. ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature;Clinical Cancer Research;2024-02-02